Recommendations for probiotic use-2011 update.

This study describes the consensus opinion of the participants of the third Yale Workshop on probiotic use. There were 10 experts participating. The recommendations update those of the first 2 meetings that were published in 2005 and 2008. The workshop presentations and papers in this supplement relate to the involvement of normal microbiota involved in intestinal microecology, how the microbes interact with the intestine to affect our immunologic responses, the stability and natural history of probiotic organisms, and the role of the intestinal microbatome with regard to affecting cardiac risk factors and obesity. Recommendations for the use of probiotics in necrotizing enterocolitis, childhood diarrhea, inflammatory bowel disease, irritable bowel syndrome, and Clostridium difficile diarrhea are reviewed. As in previous publications, the recommendations are given as A, B, or C ratings. The recent positive experiences with bacteriotherapy (fecal microbiome transplant) are also discussed in detail and a positive recommendation is made for use in severe resistant C. difficile diarrhea.

[1]  P. Brigidi,et al.  Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. , 2000, Gastroenterology.

[2]  S. Gorbach,et al.  Probiotics for Prevention of Antibiotic-associated Diarrhea , 2008, Journal of clinical gastroenterology.

[3]  H. Mykkänen,et al.  Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. , 1997, Journal of pediatric gastroenterology and nutrition.

[4]  B. Kirschner,et al.  Is Lactobacillus GG Helpful in Children With Crohn’s Disease? Results of a Preliminary, Open-Label Study , 2000, Journal of pediatric gastroenterology and nutrition.

[5]  F. Shanahan,et al.  Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. , 2005, Gastroenterology.

[6]  H A Malchow,et al.  Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? , 1997, Journal of clinical gastroenterology.

[7]  J. Katz Probiotics for the Prevention of Antibiotic-associated Diarrhea and Clostridium difficile Diarrhea , 2006, Journal of clinical gastroenterology.

[8]  D. Mack Probiotics for ulcerative colitis therapy: Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomized trial. Lancet 1999;354:635–9. , 2000 .

[9]  M. Camilleri,et al.  Recommendations for probiotic use. , 2006, Journal of clinical gastroenterology.

[10]  S. Guandalini Probiotics for Children With Diarrhea: An Update , 2008, Journal of clinical gastroenterology.

[11]  H. Suomalainen,et al.  Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobacillus casei GG. , 1995, Vaccine.

[12]  P. Testoni,et al.  Saccharomyces boulardii in Maintenance Treatment of Crohn’s Disease , 2000, Digestive Diseases and Sciences.

[13]  M. Kamm,et al.  Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis , 2003, Gut.

[14]  C. Kelly,et al.  Probiotics in clostridium difficile Infection. , 2011, Journal of clinical gastroenterology.

[15]  M. Sanders Impact of Probiotics on Colonizing Microbiota of the Gut , 2011, Journal of clinical gastroenterology.

[16]  A. Zinsmeister,et al.  A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating , 2005, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[17]  J. Minkkinen,et al.  Preservation of intestinal integrity during radiotherapy using live Lactobacillus acidophilus cultures. , 1988, Clinical radiology.

[18]  B. Rembacken,et al.  Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial , 1999, The Lancet.

[19]  P. Whorwell,et al.  Efficacy of an Encapsulated Probiotic Bifidobacterium infantis 35624 in Women with Irritable Bowel Syndrome , 2006, The American Journal of Gastroenterology.

[20]  Chyong-hsin Hsu,et al.  Oral Probiotics Prevent Necrotizing Enterocolitis in Very Low Birth Weight Preterm Infants: A Multicenter, Randomized, Controlled Trial , 2008, Pediatrics.

[21]  C. Surawicz Role of Probiotics in Antibiotic-associated Diarrhea, Clostridium difficile-associated Diarrhea, and Recurrent Clostridium difficile-associated Diarrhea , 2008, Journal of clinical gastroenterology.

[22]  G. Macfarlane,et al.  Fermentation in the Human Large Intestine: Its Physiologic Consequences and the Potential Contribution of Prebiotics , 2011, Journal of clinical gastroenterology.

[23]  P. Brigidi,et al.  High-Dose Probiotics for the Treatment of Active Pouchitis , 2007, Diseases of the colon and rectum.

[24]  K. Madsen Interactions Between Microbes and the Gut Epithelium , 2011, Journal of clinical gastroenterology.

[25]  Y. Ringel,et al.  The Rationale and Clinical Effectiveness of Probiotics in Irritable Bowel Syndrome , 2011, Journal of clinical gastroenterology.

[26]  Gregor Reid,et al.  Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis. , 2006, Microbes and infection.

[27]  E Hilton,et al.  Ingestion of Yogurt Containing Lactobacillus acidophilus as Prophylaxis for Candidal Vaginitis , 1992, Annals of Internal Medicine.

[28]  J. Bakken,et al.  Treating Clostridium difficile infection with fecal microbiota transplantation. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[29]  C. Bulpitt,et al.  Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial , 2007, BMJ : British Medical Journal.

[30]  M. Stolte,et al.  Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine , 2004, Gut.

[31]  H. Flint Obesity and the Gut Microbiota , 2011, Journal of clinical gastroenterology.

[32]  G. Reid,et al.  Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. , 2006, Microbes and infection.

[33]  S. Pergolizzi,et al.  Prevention of radiation-induced diarrhea with the use of VSL#3, a new high-potency probiotic preparation. , 2002 .

[34]  P. Lionetti,et al.  VSL#3 Improves Symptoms in Children With Irritable Bowel Syndrome: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Crossover Study , 2010, Journal of pediatric gastroenterology and nutrition.

[35]  H. Szajewska,et al.  Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. , 1998, Journal of pediatric gastroenterology and nutrition.

[36]  E. Quigley,et al.  Recommendations for probiotic use--2008. , 2008, Journal of clinical gastroenterology.

[37]  O. Chassany,et al.  Effect of a fermented milk containing Bifidobacterium animalis DN‐173 010 on the health‐related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double‐blind, controlled trial , 2007, Alimentary pharmacology & therapeutics.

[38]  H. Hricak,et al.  Evidence-based medicine. , 1997, Singapore medical journal.

[39]  S. Salminen,et al.  Probiotics: Use in Allergic Disorders: A Nutrition, Allergy, Mucosal Immunology, and Intestinal Microbiota (NAMI) Research Group Report , 2008, Journal of clinical gastroenterology.

[40]  L. Dieleman,et al.  Probiotics in the Treatment of Human Inflammatory Bowel Diseases: Update 2011 , 2011, Journal of clinical gastroenterology.

[41]  B. Birkenfeld,et al.  A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome , 2001, European journal of gastroenterology & hepatology.

[42]  P. Brigidi,et al.  Prophylaxis of pouchitis onset with probiotic therapy: A double‐blind, placebo‐controlled trial , 2000, Gastroenterology.

[43]  R. Baldassano,et al.  Effect of a Probiotic Preparation (VSL#3) on Induction and Maintenance of Remission in Children With Ulcerative Colitis , 2009, The American Journal of Gastroenterology.

[44]  R. Bibiloni,et al.  VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis , 2005, The American Journal of Gastroenterology.

[45]  W. Walker,et al.  Probiotics in the Prevention of Necrotizing Enterocolitis , 2011, Journal of clinical gastroenterology.

[46]  A. Zinsmeister,et al.  A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea‐predominant irritable bowel syndrome , 2003, Alimentary pharmacology & therapeutics.

[47]  L. Brandt,et al.  Fecal microbiota transplantation for recurrent Clostridium difficile infection , 2018, Canadian Medical Association Journal.

[48]  H. Szajewska,et al.  Meta‐analysis: Saccharomyces boulardii for treating acute diarrhoea in children , 2006, Alimentary pharmacology & therapeutics.